Skip to main content

Work in progress

Click on the links or scroll down the page for information about work currently in progress by category. Please note that information summarised on this page is subject to change.


Open consultations

We produce prescribing guidance and other medicines resources to help patients and healthcare professionals in Wales make sure that medicines are used effectively and appropriately. When we produce these resources, we think it's important that people who might be affected by them have a chance to tell us their views. 

We ask patients and carers, patient organisations, prescribers and other healthcare professionals to comment on the resources we're developing. We'd like your views on the resources we're currently working on, listed below. You don't need to comment on the whole document; only on parts that seem relevant to you.

  • We don't currently have any consultations open, but please check back here regularly for updates

Back to top


Medicines appraisals

Patients, carers and patient organisations - please see our New medicines needing your views page for answers to some questions you might have about making a submission.

Clinical experts - please see our Clinical expert opinion for medicine appraisals page for background information.

We'd like to receive your submission before the stated deadline (so we can prepare the meeting papers). But we'll still try to include any that arrive late.

Medicine name: opicapone (Ongentys®)

Reference number: 5285

Indication: Adjunctive therapy to preparations of levodopa/ DOPA decarboxylase inhibitors (DDCI) in adult patients with Parkinson's disease and end-of-dose motor fluctuations who cannot be stabilised on those combinations.

Patient and carer submission: Download form or submit online

Patient organisation submission: Download form or submit online

Clinical experts submission: Download form

Submission deadline: 20/02/2024

AWMSG meeting date: 14/05/2024

Medicine name: trifarotene (Aklief®)

Reference number: 3153

Indication: Cutaneous treatment of Acne Vulgaris of the face and/ or the trunk in patients from 12 years of age and older, when many comedones, papules and pustules are present.

Patient and carer submission: Download form or submit online

Patient organisation submission: Download form or submit online

Clinical experts submission: Download form

Submission deadline: TBC

AWMSG meeting date: 17/04/2024

Medicine name: emtricitabine/tenofovir alafenamide fumarate (Descovy®)

Reference number: 2566

Indication: Pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in at‑risk men who have sex with men, including adolescents (with body weight at least 35 kg).

Patient and carer submission: Download form or submit online

Patient organisation submission: Download form or submit online

Clinical experts submission: Download form

Submission deadline: 07/05/2023

AWMSG meeting date: 11/07/2023

Back to top


Medicines optimisation projects

Title: All Wales protocol for the appropriate prescribing of antipsychotics for people living with dementia

Status: Consultation completed

Remit: The aim of this prescribing protocol is to guide best practice in the use of antipsychotics in people living with dementia, and where possible, reduce unnecessary psychotropic prescribing.

Estimated publication date: December 2023-February 2024

Title: All Wales Policy for Medicines Administration, Recording, Review, Storage and Disposal (update)

Status: Consultation completed

Remit: This updated MARRS policy ensures practice is aligned with changes to legislation and medicines management guidelines. The guidance will ensure that medicines management is delivered in a consistent and standardised manner according to evidence-based and best practice.

Estimated publication date: December 2023-February 2024

Title:  All Wales Common Ailments Service formulary – Monograph for urinary tract infection in women

Status: Consultation completed

Remit: In August 2023, the latest iteration of the ‘All Wales Common Ailments Service formulary’ document was published following consultation and AWMSG endorsement. The Welsh Medicines Advice Service (WMAS) are now looking to add an additional monograph on urinary tract infections (UTIs) in women.

Estimated publication date: March 2024-May 2024

Title:  Initial clinical management of nicotine withdrawal in adults in secondary care

Status: Consultation completed

Remit: This is an update to the document ‘Initial clinical management of adult smokers in secondary care’. The document gives information and guidance on the initiation of nicotine replacement therapy (NRT) in secondary care settings in NHS Wales, for management of nicotine withdrawal in adults who smoke. It has been reviewed and updated to include information on the use of vapes.

Estimated publication date: March 2024-May 2024

Title:  All Wales guidance for penicillin allergy de-labelling 

Status: Consultation completed

Remit: This document provides information and guidance on the identification and removal of penicillin allergy labels in adults who have not experienced a true hypersensitivity reaction. This guidance is only intended for use in patients reporting a penicillin allergy in secondary care settings in NHS Wales.

Estimated publication date: March 2024-May 2024

Back to top


One Wales Medicine assessments

One Wales Medicine assessment

Medicine name: dabrafenib and trametinib

Reference number: OW27

Indication: For the off-label treatment of patients with locally advanced or metastatic anaplastic thyroid cancer with BRAF V600E mutation. This treatment will be limited to those patients whose tumour is deemed inoperable at the time of treatment commencement.

Patient organisation/patient/carer submission: Submit your response by email to awttc@wales.nhs.uk

Clinical experts submission: Submit your response by email to awttc@wales.nhs.uk

Submission deadline: 08/12/2023

OWMAG date: 18/03/2024

AWMSG date: 17/04/2024

One Wales Medicine assessment

Medicine name: nivolumab

Reference number: OW28

Indication: As off-label monotherapy for patients with oesophageal and gastric cancer with high microsatellite instability or mismatch repair deficiency, used in palliative care setting as first line treatment.

Patient organisation/patient/carer submission: Submit your response by email to awttc@wales.nhs.uk

Clinical experts submission: Submit your response by email to awttc@wales.nhs.uk

Submission deadline: 08/12/2023

OWMAG date: 18/03/2024

AWMSG date: 17/04/2024

Back to top


Policies, strategies and other publications

 

Title: Revised process for paediatric minor licence extensions

Summary: Revision of the paediatric licence extension appraisal process to improve access to paediatric licence extensions and facilitate access to medicines where the service benefits and/or patient need is greatest.

Estimated publication date: May/June 2023

Document: Revised process for paediatric minor licence extensions (PDF, 54Kb)

Title: Review of AWMSG processes to support medicines access in NHS Wales

Summary: Revision of processes to improve access to medicines

Estimated publication date: Summer/Autumn 2023

Document: Review of AWMSG processes to support medicines access in NHS Wales (PDF, 54Kb)

Title: AWMSG annual report 2023-2024

Summary: Review of the activities and achievements of the All Wales Medicine Strategy Group (AWMSG) between April 2023 and March 2024.

Estimated publication date: September 2024

View previous AWMSG annual reports

Title: IPFR annual report 2022-2023

Summary: Review of Individual Patient Funding Request activity in Wales between April 2022 and March 2023. 

Estimated publication date: September 2023

View previous IPFR annual reports

Title: AWMSG Five Year Strategy 2023–2028

Summary: A strategy defining the priority aims and objectives of AWMSG and partner organisations for the next five years.

Estimated publication date: October 2023

View current AWMSG strategy

Back to top

Follow AWTTC: